Skip to main content

Advertisement

SpringerLink
Log in

Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case

  • Case Report
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

A 48-year-old Japanese woman was found to have local recurrence of breast cancer in the chest wall following neoadjuvant chemotherapy, total mastectomy with axillary lymphadenectomy, postoperative radiation therapy to the chest wall, and adjuvant systemic therapy using trastuzumab. As a third line of treatment after recurrence, bevacizumab with paclitaxel was initiated for several metastatic lesions on the skin of the chest wall, left internal costal lymph nodes, and right axillary lymph nodes. The wound on the chest wall continued to expand in diameter and depth after the third course of bevacizumab with paclitaxel until the rib was exposed. After stopping the bevacizumab, granulation tissue expanded and by 3 months, had covered the bottom of the ulcer. The patient died soon thereafter, despite systemic chemotherapy with eribulin; however, there was no further bleeding from the ulcer on the chest wall or the exposed ribs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res. 2007;9:216.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth in vivo. Nature. 1993;362(6423):841–4.

    Article  CAS  PubMed  Google Scholar 

  3. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61(8):3369–72.

    CAS  PubMed  Google Scholar 

  4. Burkart CM, Grisel JJ, Hom DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008;118(9):1539–41.

    Article  CAS  PubMed  Google Scholar 

  5. Ruiz N, Fernandez Martos C, Romero I, Pla A, Maiquez J, Calatrava A, Guillem V. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007;25(22):3376–7.

    Article  PubMed  Google Scholar 

  6. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86–91.

    Article  CAS  PubMed  Google Scholar 

  7. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995;13:765–82.

    CAS  PubMed  Google Scholar 

  8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50 erratum in N Engl J Med. 2007;356:318.

    Article  CAS  PubMed  Google Scholar 

  10. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Article  PubMed  Google Scholar 

  11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Prez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  CAS  PubMed  Google Scholar 

  12. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.

    Article  CAS  PubMed  Google Scholar 

  13. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth receptor-2 negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.

    Article  CAS  PubMed  Google Scholar 

  15. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  CAS  PubMed  Google Scholar 

  16. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286–93.

    Article  CAS  PubMed  Google Scholar 

  17. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanism of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007;4(9):536–50.

    Article  CAS  PubMed  Google Scholar 

  18. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465–77.

    Article  CAS  PubMed  Google Scholar 

  20. Hamilton EP, Blackwell KL. Safety of bevacizumab in patients with metastatic breast cancer. Oncology. 2011;80:314–25.

    Article  CAS  PubMed  Google Scholar 

  21. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blinded, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.

    Article  CAS  PubMed  Google Scholar 

  22. Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs. 2009;20:197–203.

    Article  CAS  PubMed  Google Scholar 

  23. Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, Nagino M. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today. 2013 [Epub ahead of print].

  24. Tsumuraya M, Fujita M, Muroi H, Sugawara A, Tsubaki M, Kato H. A Case report-Bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for sigmoid colon cancer. Jpn J Cancer Chemother. 2011;38(11):1869–71 (abstract in English).

    Google Scholar 

  25. Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound care. 2011;20(9):403–4 406, 408 passim.

    Article  CAS  PubMed  Google Scholar 

  26. Lazzati V, Zygoń J, Lohsiriwat V, Veronesi P, Petit JY. Impaired wound healing and bilateral mastectomy flap necrosis in a patients with locally advanced breast cancer after neoadjuvant paclitaxel with bevacizumab. Aesth Plast Surg. 2010;34:796–7.

    Article  Google Scholar 

  27. Mellor JD, Cassumbhoy M, Jefford M. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol. 2011;7(2):106–13.

    Article  PubMed  Google Scholar 

  28. Pignot G, Lebret T, Chekulaev D, Peyromaure M, Saighi D, Flam T, et al. Healing and targeted therapies: management in perioperative period? Prog Urol. 2011;21(3):166–72 (in French).

    Article  CAS  PubMed  Google Scholar 

  29. Goyal S, Rao MS, Khan A, Huzzy L, Geen C, Haffty BG. Evaluation of acuter locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys. 2011;79(2):408–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan

    Yuko Kijima, Heiji Yoshinaka, Munetsugu Hirata, Akihiro Nakajo, Hideo Arima, Yoshiaki Shinden, Tetsuya Ijichi, Yuka Eguchi, Hiroshi Okumura, Yoshikazu Uenosono, Hiroshi Kurahara, Sumiya Ishigami & Shoji Natsugoe

Authors
  1. Yuko Kijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heiji Yoshinaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Munetsugu Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Nakajo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideo Arima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiaki Shinden
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuya Ijichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuka Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroshi Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshikazu Uenosono
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroshi Kurahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sumiya Ishigami
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shoji Natsugoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuko Kijima.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kijima, Y., Yoshinaka, H., Hirata, M. et al. Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case. Surg Today 45, 498–502 (2015). https://doi.org/10.1007/s00595-014-0912-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-014-0912-6

Keywords

Search

Navigation